The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 11, 2019
Filed:
Mar. 17, 2014
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
The Trustees of Columbia University IN the City of New York, New York, NY (US);
Omid C. Farokhzad, Waban, MA (US);
Xueqing Zhang, Cambridge, MA (US);
Xiaoyang Xu, Cambridge, MA (US);
Nazila Kamaly, Boston, MA (US);
Mingming Ma, Boston, MA (US);
Pedro M. Valencia, Miami, FL (US);
Robert S. Langer, Newton, MA (US);
Ira Tabas, New York, NY (US);
Gabrielle Beth Fredman, New York, NY (US);
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Massachusetts Institute of Technology, Cambridge, MA (US);
The Trustees of Columbia University in the City of New york, New York, NY (US);
Abstract
Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside 'stealth' layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation.